UCB1332: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 55 healthy volunteers showed that single doses of 15, 30, 60, 120, 240, 360 and 480 mg oral NPT200-11 were well tolerated. UCB has exclusive, ...